Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD) by 13.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 102,127 shares of the company’s stock after purchasing an additional 12,084 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned approximately 0.06% of Revolution Medicines worth $4,463,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in RVMD. IFP Advisors Inc acquired a new stake in Revolution Medicines during the fourth quarter worth about $34,000. Sterling Capital Management LLC increased its stake in Revolution Medicines by 588.7% during the fourth quarter. Sterling Capital Management LLC now owns 1,956 shares of the company’s stock worth $86,000 after acquiring an additional 1,672 shares during the last quarter. Farther Finance Advisors LLC increased its stake in Revolution Medicines by 368.3% during the fourth quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company’s stock worth $90,000 after acquiring an additional 1,613 shares during the last quarter. Kapitalo Investimentos Ltda acquired a new stake in Revolution Medicines during the fourth quarter worth about $104,000. Finally, Daiwa Securities Group Inc. increased its stake in Revolution Medicines by 521.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 3,787 shares of the company’s stock worth $165,000 after acquiring an additional 3,178 shares during the last quarter. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Revolution Medicines Stock Up 0.3%

Shares of NASDAQ RVMD opened at $39.54 on Monday. Revolution Medicines, Inc. has a fifty-two week low of $29.17 and a fifty-two week high of $62.40. The business has a 50 day moving average price of $37.49 and a two-hundred day moving average price of $43.05. The firm has a market cap of $7.37 billion, a PE ratio of -11.01 and a beta of 1.11.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.01). During the same quarter in the previous year, the business posted ($0.70) earnings per share. On average, analysts anticipate that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Insider Buying and Selling at Revolution Medicines

In other Revolution Medicines news, CFO Jack Anders sold 1,864 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $72,770.56. Following the transaction, the chief financial officer now owns 115,006 shares of the company’s stock, valued at $4,489,834.24. This trade represents a 1.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Mark A. Goldsmith sold 11,738 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $458,251.52. Following the transaction, the insider now directly owns 441,564 shares in the company, valued at approximately $17,238,658.56. This represents a 2.59% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 16,660 shares of company stock worth $650,406 in the last 90 days. 8.20% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have commented on RVMD shares. Wedbush restated an “outperform” rating and set a $67.00 price target on shares of Revolution Medicines in a research note on Thursday, May 8th. HC Wainwright restated a “buy” rating and set a $72.00 price target (down from $73.00) on shares of Revolution Medicines in a research note on Wednesday. Oppenheimer upped their price target on Revolution Medicines from $70.00 to $75.00 and gave the stock an “outperform” rating in a research note on Thursday, May 8th. Stifel Nicolaus lowered their target price on Revolution Medicines from $78.00 to $64.00 and set a “buy” rating for the company in a research note on Tuesday, April 1st. Finally, Guggenheim lowered their target price on Revolution Medicines from $87.00 to $80.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $67.08.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.